Immix Biopharma is trading 5.22% up at $13.50 in pre-market amid broad biotech strength, with XBI up 2.61%. - No fresh company-specific announcement was identified for September 23, 2026. - Mizuho raised its price target to $26 from $15 and maintained an Outperform rating on September 15; the catalyst is several sessions old, limiting confidence in a direct link to the move.